Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Lilly has a new pill, called orforglipron, it plans to launch next year. On Thursday, the company reported the results of a ...

The Huntsville Planning Commission voted to rezone 73.40 acres east of Greenbrier Road and north of Interstate 565 in ...

The City of Huntsville has taken another step toward bringing pharmaceutical giant Eli Lilly’s $6 billion facility to the ...

Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer ...

At WIRED's Big Interview event, Eli Lilly and Company's Executive Vice President and Chief Information and Digital Officer, ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

US pharma major Eli Lilly (NYSE: LLY) has reported positive topline data from its Phase III ATTAIN-MAINTAIN trial, showing that its oral GLP-1 candidate orforglipron helped patients maintain weight ...

Mainland China's 17 million Alzheimer's patients can, for the first time, pay less out of pocket for a costly drug touted as ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click ...